1647 / 1983
GEC-ESTRO APBI trial: Patient characteristics
1328 randomised from 2004 to 2009
Median age 62; Median follow-up 6.6 years
95% invasive carcinoma; 86% pT1
APBI n = 633: 119 PDR 451 HDR 8# 59 HDR 7#
90% G1-G2 75% ductal NST 92% ER+
87% adjuvant endocrine therapy 11% chemotherapy
Strnad V
et al
(2016) Lancet 387:229-238
Courtesy Chris Cottrill